Lifastuzumab vedotin

Lifastuzumab vedotin is an antibody-drug conjugate designed to treat cancer. It is composed of the monoclonal antibody lifastuzumab linked to the cytotoxic agent monomethyl auristatin E (MMAE). The antibody portion of the drug binds to HER3, a protein that is overexpressed in certain types of cancer, and delivers the cytotoxic agent directly to the cancer cells.

Mechanism of action

Lifastuzumab vedotin works by targeting the HER3 protein on the surface of cancer cells. The lifastuzumab portion of the drug binds to HER3, and the drug is then internalized by the cell. Once inside the cell, the MMAE is released and interferes with cell division, leading to cell death.

Clinical trials

Lifastuzumab vedotin has been tested in clinical trials for the treatment of various types of cancer, including breast cancer, lung cancer, and gastric cancer. However, the results of these trials have been mixed, and the drug is not currently approved for use in any country.

Side effects

The most common side effects of lifastuzumab vedotin include fatigue, nausea, and decreased appetite. More serious side effects can include neutropenia, peripheral neuropathy, and pulmonary toxicity.

See also

• List of monoclonal antibodies
• Antibody-drug conjugate
• HER3
• Monomethyl auristatin E

Lifastuzumab vedotin Resources
Need Help Finding a Doctor? WikiMD's DocFinder can help find general and specialist physicians.	Latest articles Most recent articles Ongoing trials.